Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13412427 | 0.81 | CYP1A2 (0.33) | NPC1RAB9APKMCYP1A2CYP3A4 | |
| SCHEMBL6392309 | 0.81 | PKM (0.44) | NPC1RAB9AMEN1KMT2APKM | |
| SCHEMBL8219163 | 0.78 | SLC6A3 (0.40) | SLC6A3KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7187338 | 0.77 | SLC6A3 (0.43) | SLC6A3NPC1MEN1KMT2ACYP3A4 | |
| SCHEMBL3086180 | 0.76 | CYP1A2 (0.32) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL23901916 | 0.76 | — | — | |
| SCHEMBL15319021 | 0.72 | MAPT (0.35) | NPC1RAB9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14624293 | 0.72 | SLC6A3 (0.43) | SLC6A3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL28497191 | 0.72 | SLC6A3 (0.37) | SLC6A3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL15319070 | 0.71 | SLC6A3 (0.35) | SLC6A3NPC1RAB9ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230134869-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230134869-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-4129987-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021249057-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2021-12-16 | — | — | WO | disclosed |
| US-20210355105-A1 | REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2021-11-18 | — | — | US | disclosed |
| WO-2021197452-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | 上海翰森生物医药科技有限公司 | 2021-10-07 | — | — | WO | disclosed |
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| WO-2021043077-A1 | SUBSTITUTED PYRAZINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2021-03-11 | — | — | WO | disclosed |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
| US-7935722-B2 | Tetrahydrocarbazole derivatives useful as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935722-B2 | Tetrahydrocarbazole derivatives useful as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935722-B2 | Tetrahydrocarbazole derivatives useful as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| EP-1902026-B1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) | LILLY CO ELI (US) | 2010-02-17 | — | — | EP | disclosed |
| EP-1902026-B1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) | LILLY CO ELI (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20100022550-A1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | CELLECTIS (FR) | 2010-01-28 | — | — | US | disclosed |
| US-20100022550-A1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | CELLECTIS (FR) | 2010-01-28 | — | — | US | disclosed |
| US-20100022550-A1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | CELLECTIS (FR) | 2010-01-28 | — | — | US | disclosed |
| CN-101203491-A | Tetrahydrocarbazole derivatives used as androgen receptor modifier | LILLY CO ELI (US) | 2008-06-18 | — | — | CN | disclosed |
| EP-1902026-A2 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) | ELI LILLY AND COMPANY (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007002181-A2 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) | ELI LILLY AND COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355105-A1 | REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | PTPN11, PTPN1, PTPN7 | SLC6A3 3977/4885NPC1 3735/4885RAB9A 3860/4885 |
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | PTPRJ, PTPN5, PTPN1 | SLC6A3 3970/4885NPC1 2881/4885RAB9A 1101/4885 |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | SLC6A3 4066/4885NPC1 3191/4885RAB9A 1131/4885 |
| US-20230134869-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | PTPN22, PTPN2, PTPN5 | SLC6A3 2153/4885NPC1 3387/4885RAB9A 2164/4885 |
| US-20100022550-A1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | AR, SHBG, CYP17A1 | SLC6A3 3195/4885NPC1 1593/4885RAB9A 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.